These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 37269960)
1. Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics. Patrick S; Lathoria K; Suri V; Sen E Cell Signal; 2023 Sep; 109():110738. PubMed ID: 37269960 [TBL] [Abstract][Full Text] [Related]
2. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553 [TBL] [Abstract][Full Text] [Related]
3. YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas. Patrick S; Gowda P; Lathoria K; Suri V; Sen E J Cell Sci; 2021 Nov; 134(22):. PubMed ID: 34651186 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158 [TBL] [Abstract][Full Text] [Related]
5. Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip. Cui H; Sun X; Schilling M; Herold-Mende C; Reischl M; Levkin PA; Popova AA; Turcan Ş Adv Healthc Mater; 2023 Sep; 12(24):e2300591. PubMed ID: 37162029 [TBL] [Abstract][Full Text] [Related]
6. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578 [TBL] [Abstract][Full Text] [Related]
8. Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence. Guichet PO; Masliantsev K; Tachon G; Petropoulos C; Godet J; Larrieu D; Milin S; Wager M; Karayan-Tapon L J Pathol; 2018 Oct; 246(2):205-216. PubMed ID: 30009411 [TBL] [Abstract][Full Text] [Related]
9. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas. Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035 [TBL] [Abstract][Full Text] [Related]
10. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of ZEB1 and YAP1 is related to poor prognosis in patients with gliomas with different IDH1 status. Miao N; Wang ZQ; Zhang N; Ma ZP; Su LP; Zhai YY; Hu YR; Sang W; Zhang W Int J Clin Exp Pathol; 2023; 16(7):138-149. PubMed ID: 37559682 [TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508 [TBL] [Abstract][Full Text] [Related]
13. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978 [No Abstract] [Full Text] [Related]
14. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas. Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678 [TBL] [Abstract][Full Text] [Related]
15. IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT. Tong S; Wu J; Song Y; Fu W; Yuan Y; Zhong P; Liu Y; Wang B Cell Death Discov; 2024 Jul; 10(1):317. PubMed ID: 38982076 [TBL] [Abstract][Full Text] [Related]
16. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma. Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238 [TBL] [Abstract][Full Text] [Related]
18. High levels of TIMP1 are associated with increased extracellular matrix stiffness in isocitrate dehydrogenase 1-wild type gliomas. Luo CH; Shi Y; Liu YQ; Liu Q; Mao M; Luo M; Yang KD; Wang WY; Chen C; Niu Q; Yan ZX; Miao JY; Zhang XN; Zeng H; Li L; Bian XW; Ping YF Lab Invest; 2022 Dec; 102(12):1304-1313. PubMed ID: 35882906 [TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET. Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598 [TBL] [Abstract][Full Text] [Related]
20. CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma. Wang S; Wu J; Zhao W; Li M; Li S FASEB J; 2023 Apr; 37(4):e22848. PubMed ID: 36906285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]